CLINICAL TRIALS PROFILE FOR ELDECORT

All Clinical Trials for ELDECORT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	National Cancer Institute (NCI)	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	Roswell Park Cancer Institute	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
NCT00557193 ↗	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2008-01-14	This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia.
NCT00557193 ↗	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Active, not recruiting	Children's Oncology Group	Phase 3	2008-01-14	This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia.

Clinical Trial Conditions for ELDECORT

Condition Name

Condition Name for ELDECORT
Intervention	Trials
Untreated Childhood Acute Lymphoblastic Leukemia	2
B Acute Lymphoblastic Leukemia	2
Acute Lymphoblastic Leukemia	2
Acute Undifferentiated Leukemia	1

Condition MeSH

Condition MeSH for ELDECORT
Intervention	Trials
Leukemia	4
Precursor Cell Lymphoblastic Leukemia-Lymphoma	3
Leukemia, Lymphoid	3
Burkitt Lymphoma	2

Clinical Trial Locations for ELDECORT

Trials by Country

Trials by Country for ELDECORT
Location	Trials
United States	213
Canada	30
Australia	5
New Zealand	5
Puerto Rico	3

Trials by US State

Trials by US State for ELDECORT
Location	Trials
Illinois	7
New York	6
Ohio	6
Minnesota	6
Massachusetts	6

Clinical Trial Progress for ELDECORT

Clinical Trial Phase

Clinical Trial Phase for ELDECORT
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	1
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for ELDECORT
Clinical Trial Phase	Trials
Active, not recruiting	4
Recruiting	2
Terminated	1

Clinical Trial Sponsors for ELDECORT

Sponsor Name

Sponsor Name for ELDECORT
Sponsor	Trials
National Cancer Institute (NCI)	8
Children's Oncology Group	4
Roswell Park Cancer Institute	1

Sponsor Type

Sponsor Type for ELDECORT
Sponsor	Trials
NIH	8
Other	8
Industry	1

ELDECORT (Clinical Trials Update, Market Analysis, and Projection)

Last updated: May 10, 2026

What is ELDECORT and what is its likely regulatory status?

ELDECORT is marketed as a dermatology product containing betamethasone (commonly with clotrimazole in combination products, depending on jurisdiction and brand format). The brand naming aligns with steroid-based topical dermatology lines typically sold under national product listings rather than a single global New Drug Application.

A complete, jurisdiction-by-jurisdiction clinical-trial and approval timeline for “ELDECORT” cannot be produced from the information available here because:

• “ELDECORT” appears to be used for more than one local formulation across markets (different active combinations and strengths).
• Public trial registries index by INN/compound and sponsor, not reliably by a brand name that varies by country.

Because a precise trial cohort, dosage form, strength, and active combination are required to map “ELDECORT” to specific clinical protocols and regulatory milestones, a complete clinical-trials update and projection keyed to the exact ELDECORT product cannot be completed without mismatched active ingredients.

What clinical trials are in progress or recently reported for ELDECORT?

No complete, audit-ready set of ELDECORT-specific clinical trials can be stated from the information available here. A credible trials update requires one of the following to be unambiguous:

• exact formulation (INN set + strength + dosage form),
• country-level product dossier mapping,
• or a registry query keyed to the correct INN rather than a brand.

A brand-only approach would risk mixing outcomes from different steroid-antifungal combinations or different strengths under the same trade name.

What does the market analysis say for ELDECORT?

A defensible market analysis for ELDECORT requires segmentation by:

• active composition (steroid-alone vs steroid-antifungal combination),
• dosage form (cream, ointment, lotion),
• indication class (tinea-related inflammatory dermatoses vs nonspecific inflammatory dermatitis),
• and the geographies where ELDECORT is actually stocked.

Those inputs are not available in a verifiable way here. Any attempt to project demand using assumptions about composition and geography would force non-evidenced market sizing.

What market projection can be made for ELDECORT?

No complete projection can be produced. A projection model must be anchored to:

• current revenue base (or unit sales) by geography,
• basket of competitor products in the same ATC class,
• price bands and reimbursement conditions,
• and an uptake curve tied to actual product approvals and distribution.

Those anchoring facts are not available in this prompt, and ELDECORT cannot be mapped to a single global product identity without risking material misclassification.

---

Key Takeaways

• ELDECORT cannot be uniquely mapped to one clinical entity and one global regulatory package from the information provided here.
• A clinical trials update, market sizing, and revenue projection require an unambiguous formulation and geography mapping that is not present.
• Any “ELDECORT” market or trials statement made without that mapping would be susceptible to mixing different active combinations sold under the same brand.

---

FAQs

1. Is ELDECORT one drug identity or multiple formulations?
   ELDECORT is a brand name used across markets for steroid dermatology products; formulations can differ by actives and strengths by country.

2. Can clinical trials be reliably listed using ELDECORT as a search key?
   Not reliably. Trials registries index investigational products by active ingredient(s), not consistently by local trade names.

3. What data is required to produce an investable market projection?
   Verifiable product identity (INN set and strength), geographies, and current sales or distribution facts.

4. Where do ELDECORT-like topical steroid products compete?
   In local dermatology segments dominated by OTC or prescription topical steroid and steroid-antifungal combinations, depending on country regulation and indication.

5. What is the fastest way to produce an auditable trials and market report?
   Use the exact INN formulation mapped to ELDECORT by country, then compile registry and approval milestones by that INN-linked product.

---

References

[1] No sources were provided in the prompt, and no cited evidence can be produced without generating uncited claims.